U.S., Nov. 26 -- ClinicalTrials.gov registry received information related to the study (NCT07248176) titled 'Universal CAR-T Cell Therapy for MM' on Nov. 18.
Brief Summary: This trial aims to evaluate the safety and efficacy of BCMA-UCART in treating patients with r/r multiple myeloma.
Study Start Date: April 10
Study Type: INTERVENTIONAL
Condition:
Multiple Myeloma
Multiple Myeloma in Relapse
Multiple Myeloma, Refractory
Intervention:
DRUG: Targeted BCMA Gene-Modified Allogeneic Chimeric Antigen Receptor T-Cell Injection
The study drug is administered intravenously at a fixed dose within 1-2 days after lymphocyte depletion, and its efficacy and safety are observed.
Recruitment Status: RECRUITING
Sponsor: Bioray Laboratories
Disc...